INNV (MC $7 M) 2x Drugs launched & 3x Approvals in 2Q 2014 / Low Float 10 M = TGT $5++

Discussion in 'Stock picks and trading strategies' started by DollarChamp, Mar 7, 2014.

  1. DollarChamp

    DollarChamp Member

    Thats a Stock called a REAL LIFETIME OPPORTUNITY . Please Do your own DD and you will know why .GL

    This Unknown Goldmine has two big Products since a few days ago and another three Products will be launched in 2Q 2014 . More Partner Deals coming soon which will bring more Cash to the Company . The Most of the Products targeting a Multi-Billion-Dollar Market . CEO says main goal for 2014 is Nasdaq-Listing means he expect that this Low Float Rocket to move over $3 because this is a requirement for Nasdaq-Listing .

    At $10 this Stock would have a Market Cap of Only $170 M and thats achievable with their Products which have HUGE Market Potential .



    Innovus Pharmaceutical (INNV)

    Market Cap: $7 Million
    Cash : $1.2 M
    Price: $0.38

    Shares Out : 18.1 Million
    Float : 10 Million


    Innovus introduces premature ejaculation drug EjectDelay in US (24 February 2014)
    http://otc.pharmaceutical-business-...culation-drug-ejectdelay-in-us-240214-4183187


    Monster Pipeline :

    Product Route Stage Disease Territory Exp.Launch Date

    CIRCUMserum™ Topical OTC Reduced Penile Sensitivity Ex-US Marketed

    EjectDelay™ Topical OTC Compliant Premature Ejaculation Worldwide Q1 2014

    Apeaz™ Topical OTC Compliant Arthritis Pain Worldwide Q1 2014

    Acne Care Topical OTC Registration Acne Treatment Worldwide Q2 2014

    Cough/Cold Lozenges Oral OTC Cough & Cold Reduction Worldwide Q2 1014

    Xyralid™ Topical OTC Registration Anesthetic Worldwide Q2 2014

    -----

    CEO holding over 6 Mil shrs thats almost 35% of the 18 M Shrs Outstanding and he currently financing the Company with his own money . Its always a good sign when CEO support the Company like this way .

    http://data.cnbc.com/quotes/INNV/tab/8
    Major Shareholders of Innovus ( Shares Outstanding : 18.1 M ) :

    Damaj (Bassam B) ... 6.2M
    Esber (Henry Jemil) ...2.5M
    Quaker Partners ...1.6M
    Liu (Vivian H) .....990.9K
    Jadra (Ramon) .....989.2K
    Boyack (Wallace) ....840.6K
    Mirza (Ziad) ....429.2K


    Info about the CEO :

    Damaj took the reins of Innovus as CEO in January, 2013. In his previous position at Apricus Biosciences, the market cap of Apricus grew from $17 million to more than $100 million. During Damaj's tenure at Apricus,partnerships were signed with companies such as Abbott, Sandoz, and Takeda


    http://www.news-medical.net/news/20...th-Dr-Bassam-Damaj-CEO-of-Innovus-Pharma.aspx

    [h=2]What excites you the most about Innovus’ product pipeline right now?[/h] Innovus has built an impressive commercial pipeline in a very short period of time. I am excited about the fact that we have the product which will allow us to do commercial partnerships and start generating revenues for the company.
    [h=2]How strong is the market for these products predicted to be over the next 3-5 years?[/h] Our products are for diseases in the sexual dysfunction, dermatology, respiratory and inflammation/pain areas. Those are big markets and the number of patients is on the rise year after year.
    [h=2]What are Innovus’ plans for the future?[/h] Innovus’ plans are very clear and focused. We are working towards commercial partnerships for our product to start generating revenues on a worldwide basis towards our main goal of listing the company on Nasdaq in 2014.
     
  2. jakebvt

    jakebvt New Member

    They don't have a solid history in my book. Financials don't look too good.

    BU4ANZi.png
    JR3OsSk.png
    QlMLgOg.png

    Oh, and Net Profit Margin:
    -790431.10%
     
  3. Blaine Tarr

    Blaine Tarr forum leader won penny contest 24x won weekly contest 20x

    You really can't worry about that kind of info on these junk stocks as they are all losing money. Only thing that matters is the potential to have potential; in this case a pipeline of drugs; and the price action of buyers and sellers. Charting is my best friend.

    That said, DollarChamp pumps alot of these junk bio-techs. Some go, some don't. The volume isn't there, and never will be as its a low floater. But that's also why it could run quickly if a few bigger buyers bring heat. That's what he's counting on eventually, so he hypes the story......
     
Loading...

Share This Page